ClinicalTrials.gg
Enrolling by invitationNCT07283978RENEWUpdated Oct 23, 2026

Real-world Exploration of Digital iNnovation in the Management of Excess Weight

An interventional study of Digital Weight Management Programme in Obesity and Obesity & Overweight, sponsored by Guy's and St Thomas' NHS Foundation Trust. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
580
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Obesity with a site in United Kingdom — 94 open to participants now, 128 under way, 41 of them phase 3. Obesity · United Kingdom.

Planned enrollment
65th of 372
580 · median 66
Started
2025
with 33 others
No phase
225 of 454
38 open now
Primary completion
2027-11
later than 64 of 127 live
Registered
399th of 454
by date

Among the 454 studies in Obesity with a site in United Kingdom, this one is the 65th largest by planned enrollment of the 372 interventional ones that give a count, is one of 34 that started in 2025, is one of 225 with no phase, reaches primary completion later than 64 of the 127 other live ones, and was the 399th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

94 of the 454 studies in Obesity with a site in United Kingdom are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Obesity with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a real-world study. The purpose of this research is to explore whether a new National Institute for Health and Care Excellence (NICE)-approved digital weight-management model of care can improve health service delivery and address the Quintuple Aim of Healthcare (health outcomes, cost, patient and clinician experience, and health inequalities), for individuals living with obesity accessing National Health Service (NHS) Tier 3 weight-management services.

03

Conditions studied

  • Obesity
  • Obesity & Overweight

Keywords

  • Weight Management
  • Digital Weight Management
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Referred to South east London Tier 3 weight management pathway by their GP
  • Accepted by the GSTT Tier 3 weight management service

Exclusion criteria

Exclusion Criteria:

  • Participants is Group A cannot participate in Group B
  • Do not have use of a smartphone
  • Do not read, write, or speak English
  • Are unable and/or unwilling to provide
  • Have a diagnosis of an eating disorder
  • Have had bariatric surgery
  • Currently have deranged thyroid function tests (required as part of normal referral process)
  • Have type-1 diabetes
  • Are on insulin or sulfonylureas at high risk of hypoglycaemia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
580 participants (estimated)

Study arms

  • Active comparator
    Group A Intervention

    Study participants who receive 12 months of digital weight management services delivered through a smartphone app.

    Other: Digital Weight Management Programme

  • Active comparator
    Group B Intervention

    Study participants who receive 12 months of digital weight management services delivered through a smartphone app

    Other: Digital Weight Management Programme

  • No intervention
    Group A Controls

    Patients who receive standard of care weight management services

  • No intervention
    Group B Controls

    Patients who receive standard of care service after discharge from standard of care weight management services

Interventions

  • OtherDigital Weight Management Programme

    Digital Weight Management Programme

06

What researchers measure

Primary outcomes

  1. Percentage of weight change at 12 months

    Time frame: Baseline and 12 months

  2. Quality of Life as a measure to determine cost-effectiveness

    Quality of Life will be measured using the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) questionnaire

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Feasibility of implementing the intervention into Tier 3 weight management pathways

    This will be assessed through qualitative interviews with participants in the Sub-study.

    Time frame: Once

  2. Acceptability of implementing the intervention into Tier 3 weight management pathways

    This will be assessed through qualitative interviews with participants in the Sub-study.

    Time frame: Once

  3. Uptake of the intervention

    Time frame: 12 months

  4. Retention in the intervention programme

    Time frame: From enrolment until the end of the intervention at 12 months /withdrawal/dropout

  5. Success in the intervention programme

    This will be assessed as clinically significant percentage in weight change of greater than or equal to 5 percent.

    Time frame: From enrolment until the end of the intervention at 12 months

  6. Economic measurements - Quality of Life Years

    Quality-Adjusted Life Years (QALYs) associated with weight loss, calculated from the scores on the European Quality of Life 5 Dimensions Level questionnaire (EQ-5D-5L)

    Time frame: Baseline, 6 months, and 12 months

  7. Economics measurements - Resource Use

    Resource use covering primary and secondary care services within the National Health Service (NHS)

    Time frame: From enrolment to the end of the intervention at 12 months

  8. Economics measurements - Unit costs

    Unit costs obtained from standard sources such as NHS reference costs and Personal Social Services Research Unit's unit costs for health and social care.

    Time frame: From enrolment to end of intervention at 12 months

  9. Economics measurements - Costs between intervention group and standard care group

    Costs between intervention group and standard care group with be compared

    Time frame: From enrolment to end of intervention at 12 months

  10. Patient reported outcomes - alcohol use

    This will be assessed using a self-reported questionnaire - Alcohol Use Disorders Identification Test (Audit) / scale ranges 0 - 40 / 0=low risk, 20 or more = possible alcohol dependence

    Time frame: At Baseline, 6 months, and 12 months

  11. Patient reported outcomes - patient health

    This will be assessed using the self-reported Patient Health Questionnaire-4 (PH-4) / Score range 0 - 12) / Score of 3 or higher further assessment for depression \&/or anxiety recommended

    Time frame: Baseline, 6 months, 12 months

  12. Patient reported outcomes - eating pattern

    This will be assessed using the self-reported Three-Factor Eating Questionnaire / Score range 1 - 4 for each question / scores are summated into scale scores for cognitive restraint, uncontrolled eating, and emotional eating.

    Time frame: Baseline, 6 months, 12 months

  13. Patient reported outcomes - binge eating

    This will be assessed using the self-reported Binge Eating Scale (BES) questionnaire / Score range 0 - 46 / 17 or lower = low binge-eating, 18-26 = mild to moderate binge-eating, 27 or higher = severe binge-eating

    Time frame: Baseline

  14. Patient reported outcomes - physical activity

    This will be assess using the self-reported General Practice Physical Activity Questionnaires / Scoring is: Inactive, Moderately inactive, Moderately active, or Active

    Time frame: Baseline if required per clinician assessment

  15. Sub-group analyses- Use of glucagon-like peptide (GLP-1) agonists

    Participant use (never/commenced during study/used throughout) of GLP-1 agonsits will be assessed

    Time frame: From enrolment until the end of intervention at 12 months

  16. Sub-group analyses - Adherence

    Participant adherence to the intervention will be assessed

    Time frame: From enrolment until drop-out, withdrawal, or end of intervention at 12 months

  17. Sub-group analyses - Comorbidities

    Obesity-related medical comorbidities will be assessed

    Time frame: From enrolment until end of intervention at 12 months

  18. Sub-group analyses - Social demographics

    Participant social demographics such as sex, ethnicity, age, and Index of Multiple Deprivation (IMD) will be assessed.

    Time frame: At enrolment

  19. Clinical measures - height

    Height in metres will be assessed as part of the clinical measures analysis

    Time frame: Baseline

  20. Clinical measures - blood pressure

    Self-reported blood pressure will be assessed as part of the clinical measures analysis

    Time frame: Baseline, 6 months, and 12 months

  21. Clinical measures - Body Mass Index

    Body Mass Index (BMI) will be assessed from self-reported weight in kilograms divided by height in metres squared, as part of the clinical measures analysis.

    Time frame: Baseline, 6 months, and 12 months

  22. Clinical Measures - waist circumference

    Self-reported waist circumference in centimetres will assessed as part of the clinical measures analysis

    Time frame: Baseline, 6 months, 12 months

07

Study locations

1 site
  • Guy' & St Thomas' NHS Foundation Trust
    London, Greater London SE1 9RT, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — IPD will be shared on reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 16, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and data sharing statement
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07283978
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 16, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Andrew Walker, PhD
study chair · Guy's and St Thomas' NHS Foundation Trust
Emma Duncan, MD, PhD
study director · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion